Molecular and epigenetic basis of macrophage polarized activation

Seminars in Immunology

Volumn 27, Issue 4, 2015, Pages 237-248

  Porta, Chiara ^a   Riboldi, Elena ^a   Ippolito, Alessandro ^a   Sica, Antonio ^a,b  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Activation; Epigenetic; Gene expression; Macrophage; Metabolism; Plasticity

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; HISTONE DEACETYLASE 3; INTERFERON REGULATORY FACTOR 5; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 4; KRUPPEL LIKE FACTOR; KRUPPEL LIKE FACTOR 4; MICRORNA 124; MICRORNA 155; MICRORNA 223; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN E2; STAT1 PROTEIN; STAT3 PROTEIN; STAT6 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING;

CELL DIFFERENTIATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN STRUCTURE; CYTOKINE PRODUCTION; EPIGENETICS; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; LUNG TRANSPLANTATION; MACROPHAGE; MACROPHAGE ACTIVATION; MACROPHAGE POLARIZED ACTIVATION; NONHUMAN; NUCLEAR REPROGRAMMING; PLASTICITY; POLARIZATION; PROTEIN EXPRESSION; REVIEW; SEPSIS; ANIMAL; GENETIC EPIGENESIS; IMMUNOLOGY; NEOPLASM; OBESITY; WOUND HEALING;

ANIMALS; EPIGENESIS, GENETIC; HUMANS; INFLAMMATION; MACROPHAGE ACTIVATION; NEOPLASMS; OBESITY; WOUND HEALING;

EID: 84950284907     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2015.10.003     Document Type: Review

References (207)

1. Wynn T.A., Chawla A., Pollard J.W. Macrophage biology in development, homeostasis and disease. Nature 2013, 496(7446):445-455.
2. Murray P.J., Wynn T.A. Protective and pathogenic functions of macrophage subsets. Nat. Rev. Immunol. 2011, 11(11):723-737.
3. Gordon S., Pluddemann A., Martinez Estrada F. Macrophage heterogeneity in tissues: phenotypic diversity and functions. Immunol. Rev. 2014, 262(1):36-55.
4. Davies L.C., et al. Tissue-resident macrophages. Nat. Immunol. 2013, 14(10):986-995.
5. Ginhoux F., et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 2010, 330(6005):841-845.
6. Schulz C., et al. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science 2012, 336(6077):86-90.
7. Yona S., et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity 2013, 38(1):79-91.
8. Hashimoto D., et al. Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. Immunity 2013, 38(4):792-804.
9. Epelman S., et al. Embryonic and adult-derived resident cardiac macrophages are maintained through distinct mechanisms at steady state and during inflammation. Immunity 2014, 40(1):91-104.
10. Gomez Perdiguero E., et al. Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors. Nature 2015, 518(7540):547-551.
11. Epelman S., Lavine K.J., Randolph G.J. Origin and functions of tissue macrophages. Immunity 2014, 41(1):21-35.
12. Sheng J., Ruedl C., Karjalainen K. Most tissue-resident macrophages except microglia are derived from fetal hematopoietic stem cells. Immunity 2015, 43(2):382-393.
13. Hoeffel G., et al. C-Myb(+) erythro-myeloid progenitor-derived fetal monocytes give rise to adult tissue-resident macrophages. Immunity 2015, 42(4):665-678.
14. Zigmond E., et al. Ly6 C hi monocytes in the inflamed colon give rise to proinflammatory effector cells and migratory antigen-presenting cells. Immunity 2012, 37(6):1076-1090.
15. Bain C.C., et al. Resident and pro-inflammatory macrophages in the colon represent alternative context-dependent fates of the same Ly6Chi monocyte precursors. Mucosal Immunol. 2013, 6(3):498-510.
16. Tamoutounour S., et al. Origins and functional specialization of macrophages and of conventional and monocyte-derived dendritic cells in mouse skin. Immunity 2013, 39(5):925-938.
17. Kanitakis J., et al. Self-renewal capacity of human epidermal Langerhans cells: observations made on a composite tissue allograft. Exp. Dermatol. 2011, 20(2):145-146.
18. Bigley V., Collin M. Dendritic cell, monocyte, B and NK lymphoid deficiency defines the lost lineages of a new GATA-2 dependent myelodysplastic syndrome. Haematologica 2011, 96(8):1081-1083.
19. Collin M.P., et al. The fate of human Langerhans cells in hematopoietic stem cell transplantation. J. Exp. Med. 2006, 203(1):27-33.
20. Haniffa M., et al. Differential rates of replacement of human dermal dendritic cells and macrophages during hematopoietic stem cell transplantation. J. Exp. Med. 2009, 206(2):371-385.
21. Bigley V., et al. The human syndrome of dendritic cell, monocyte, B and NK lymphoid deficiency. J. Exp. Med. 2011, 208(2):227-234.
22. Gautier E.L., et al. Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. Nat. Immunol. 2012, 13(11):1118-1128.
23. Lavin Y., et al. Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment. Cell 2014, 159(6):1312-1326.
24. Gosselin D., et al. Environment drives selection and function of enhancers controlling tissue-specific macrophage identities. Cell 2014, 159(6):1327-1340.
25. Gibbings S.L., et al. Transcriptome analysis highlights the conserved difference between embryonic and postnatal-derived alveolar macrophages. Blood 2015, 126(11):1357-1366.
26. Biswas S.K., Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 2010, 11(10):889-896.
27. Sica A., Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J. Clin. Invest. 2012, 122(3):787-795.
28. Mosser D.M., Edwards J.P. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 2008, 8(12):958-969.
29. Gadler T., Gardiner A., Martinez N. Caring for the postoperative patient with complications presenting to the emergency department. Adv. Emerg. Nurs. J. 2014, 36(2):134-144.
30. Stout R.D., Suttles J. Functional plasticity of macrophages: reversible adaptation to changing microenvironments. J. Leukoc. Biol. 2004, 76(3):509-513.
31. Ostuni R., et al. Latent enhancers activated by stimulation in differentiated cells. Cell 2013, 152(1-2):157-171.
32. Kaikkonen M.U., et al. Remodeling of the enhancer landscape during macrophage activation is coupled to enhancer transcription. Mol. Cell 2013, 51(3):310-325.
33. Porta C., et al. Macrophages in cancer and infectious diseases: the 'good' and the 'bad'. Immunotherapy 2011, 3(10):1185-1202.
34. Mantovani A., Allavena P. The interaction of anticancer therapies with tumor-associated macrophages. J. Exp. Med. 2015, 212(4):435-445.
35. Liu Y.C., et al. Macrophage polarization in inflammatory diseases. Int. J. Biol. Sci. 2014, 10(5):520-529.
36. Biswas S.K., et al. Macrophage polarization and plasticity in health and disease. Immunol. Res. 2012, 53(1-3):11-24.
37. Mantovani A., Allavena P. The interaction of anticancer therapies with tumor-associated macrophages. J. Exp. Med. 2015, 212(4):435-445.
38. Pollard J.W. Trophic macrophages in development and disease. Nat. Rev. Immunol. 2009, 9(4):259-270.
39. Boyle W.J., Simonet W.S., Lacey D.L. Osteoclast differentiation and activation. Nature 2003, 423(6937):337-342.
40. Nagata S. Autoimmune diseases caused by defects in clearing dead cells and nuclei expelled from erythroid precursors. Immunol. Rev. 2007, 220:237-250.
41. Chow A., et al. CD169(+) macrophages provide a niche promoting erythropoiesis under homeostasis and stress. Nat. Med. 2013, 19(4):429-436.
42. den Haan J.M., Kraal G. Innate immune functions of macrophage subpopulations in the spleen. J. Innate Immun. 2012, 4(5-6):437-445.
43. Michelucci A., et al. The KIT Exon 11 stop codon mutation in gastrointestinal stromal tumors: what is the clinical meaning?. Gut Liver 2013, 7(1):35-40.
44. Cai Y., et al. In vivo characterization of alveolar and interstitial lung macrophages in rhesus macaques: implications for understanding lung disease in humans. J. Immunol. 2014, 192(6):2821-2829.
45. Schneberger D., Aharonson-Raz K., Singh B. Monocyte and macrophage heterogeneity and Toll-like receptors in the lung. Cell Tissue Res. 2011, 343(1):97-106.
46. Duan M., et al. Distinct macrophage subpopulations characterize acute infection and chronic inflammatory lung disease. J. Immunol. 2012, 189(2):946-955.
47. Guilliams M., et al. Alveolar macrophages develop from fetal monocytes that differentiate into long-lived cells in the first week of life via GM-CSF. J. Exp. Med. 2013, 210(10):1977-1992.
48. Schneider C., et al. Induction of the nuclear receptor PPAR-gamma by the cytokine GM-CSF is critical for the differentiation of fetal monocytes into alveolar macrophages. Nat. Immunol. 2014, 15(11):1026-1037.
49. Hoeffel G., et al. Adult Langerhans cells derive predominantly from embryonic fetal liver monocytes with a minor contribution of yolk sac-derived macrophages. J. Exp. Med. 2012, 209(6):1167-1181.
50. Misharin A.V., et al. Flow cytometric analysis of macrophages and dendritic cell subsets in the mouse lung. Am. J. Respir. Cell Mol. Biol. 2013, 49(4):503-510.
51. Carey B., Trapnell B.C. The molecular basis of pulmonary alveolar proteinosis. Clin. Immunol. 2010, 135(2):223-235.
52. Maus U.A., et al. Role of resident alveolar macrophages in leukocyte traffic into the alveolar air space of intact mice. Am. J. Physiol. Lung Cell Mol. Physiol. 2002, 282(6):L1245-L1252.
53. Rajaram M.V., et al. Macrophage immunoregulatory pathways in tuberculosis. Semin. Immunol. 2014, 26(6):471-485.
54. Westphalen K., et al. Sessile alveolar macrophages communicate with alveolar epithelium to modulate immunity. Nature 2014, 506(7489):503-506.
55. Bourdonnay E., et al. Transcellular delivery of vesicular SOCS proteins from macrophages to epithelial cells blunts inflammatory signaling. J. Exp. Med. 2015, 212(5):729-742.
56. Bedoret D., et al. Lung interstitial macrophages alter dendritic cell functions to prevent airway allergy in mice. J. Clin. Invest. 2009, 119(12):3723-3738.
57. Schneberger D., Aharonson-Raz K., Singh B. Pulmonary intravascular macrophages and lung health: what are we missing?. Am. J. Physiol. Lung Cell Mol. Physiol. 2012, 302(6):L498-L503.
58. Tay S.S., et al. The skin-resident immune network. Curr. Dermatol. Rep. 2014, 3:13-22.
59. Malissen B., Tamoutounour S., Henri S. The origins and functions of dendritic cells and macrophages in the skin. Nat. Rev. Immunol. 2014, 14(6):417-428.
60. Schulz O., Pabst O. Antigen sampling in the small intestine. Trends Immunol. 2013, 34(4):155-161.
61. Cros J., et al. Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity 2010, 33(3):375-386.
62. Carlin L.M., et al. Nr4a1-dependent Ly6C (low) monocytes monitor endothelial cells and orchestrate their disposal. Cell 2013, 153(2):362-375.
63. Ingersoll M.A., et al. Comparison of gene expression profiles between human and mouse monocyte subsets. Blood 2010, 115(3):pe10-pe19.
64. Hanna R.N., et al. The transcription factor NR4A1 (Nur77) controls bone marrow differentiation and the survival of Ly6C- monocytes. Nat. Immunol. 2011, 12(8):778-785.
65. Jakubzick C., et al. Minimal differentiation of classical monocytes as they survey steady-state tissues and transport antigen to lymph nodes. Immunity 2013, 39(3):599-610.
66. Dey A., Allen J., Hankey-Giblin P.A. Ontogeny and polarization of macrophages in inflammation: blood monocytes versus tissue macrophages. Front Immunol. 2014, 5:683.
67. Benakis C., et al. The role of microglia and myeloid immune cells in acute cerebral ischemia. Front. Cell Neurosci. 2014, 8:461.
68. Goritzka M., et al. Alveolar macrophage-derived type I interferons orchestrate innate immunity to RSV through recruitment of antiviral monocytes. J. Exp. Med. 2015, 212(5):699-714.
69. Tamura T., Kurotaki D., Koizumi S. Regulation of myelopoiesis by the transcription factor IRF8. Int. J. Hematol. 2015, 101(4):342-351.
70. Rosas M., et al. The transcription factor Gata6 links tissue macrophage phenotype and proliferative renewal. Science 2014, 344(6184):645-648.
71. Okabe Y., Medzhitov R. Tissue-specific signals control reversible program of localization and functional polarization of macrophages. Cell 2014, 157(4):832-844.
72. Kodama H., et al. Essential role of macrophage colony-stimulating factor in the osteoclast differentiation supported by stromal cells. J. Exp. Med. 1991, 173(5):1291-1294.
73. Boyce B.F., et al. NF-kappaB-mediated regulation of osteoclastogenesis. Endocrinol. Metab. (Seoul) 2015, 30(1):35-44.
74. Kohyama M., et al. Role for Spi-C in the development of red pulp macrophages and splenic iron homeostasis. Nature 2009, 457(7227):318-321.
75. Haldar M., et al. Heme-mediated SPI-C induction promotes monocyte differentiation into iron-recycling macrophages. Cell 2014, 156(6):1223-1234.
76. Stein M., et al. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J. Exp. Med. 1992, 176(1):287-292.
77. Murray P.J., et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 2014, 41(1):14-20.
78. Mantovani A., et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004, 25(12):677-686.
79. Biswas S.K., Mantovani A. Orchestration of metabolism by macrophages. Cell Metab. 2012, 15(4):432-437.
80. Ganeshan K., Chawla A. Metabolic regulation of immune responses. Annu. Rev. Immunol. 2014, 32:609-634.
81. Galvan-Pena S., O'Neill L.A. Metabolic reprograming in macrophage polarization. Front. Immunol. 2014, 5:p420.
82. Recalcati S., Locati M., Cairo G. Systemic and cellular consequences of macrophage control of iron metabolism. Semin. Immunol. 2012, 24(6):393-398.
83. Rath M., et al. Metabolism via arginase or nitric oxide synthase: two competing arginine pathways in macrophages. Front. Immunol. 2014, 5:p532.
84. Lu G., et al. Myeloid cell-derived inducible nitric oxide synthase suppresses M1 macrophage polarization. Nat. Commun. 2015, 6:p6676.
85. Rodriguez-Prados J.C., et al. Substrate fate in activated macrophages: a comparison between innate, classic, and alternative activation. J. Immunol. 2010, 185(1):605-614.
86. Haschemi A., et al. The sedoheptulose kinase CARKL directs macrophage polarization through control of glucose metabolism. Cell Metab. 2012, 15(6):813-826.
87. West A.P., et al. TLR signalling augments macrophage bactericidal activity through mitochondrial ROS. Nature 2011, 472(7344):476-480.
88. Jha A.K., et al. Network integration of parallel metabolic and transcriptional data reveals metabolic modules that regulate macrophage polarization. Immunity 2015, 42(3):419-430.
89. Infantino V., et al. The mitochondrial citrate carrier: a new player in inflammation. Biochem. J. 2011, 438(3):433-436.
90. Michelucci A., et al. Immune-responsive gene 1 protein links metabolism to immunity by catalyzing itaconic acid production. Proc. Natl. Acad. Sci. U.S.A. 2013, 110(19):7820-7825.
91. Tannahill G.M., et al. Succinate is an inflammatory signal that induces IL-1beta through HIF-1alpha. Nature 2013, 496(7444):238-242.
92. Vats D., et al. Oxidative metabolism and PGC-1beta attenuate macrophage-mediated inflammation. Cell Metab. 2006, 4(1):13-24.
93. Martinez F.O., et al. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J. Immunol. 2006, 177(10):7303-7311.
94. Langer C., et al. Testosterone up-regulates scavenger receptor BI and stimulates cholesterol efflux from macrophages. Biochem. Biophys. Res. Commun. 2002, 296(5):1051-1057.
95. Gordon S. Alternative activation of macrophages. Nat. Rev. Immunol. 2003, 3(1):23-35.
96. Qualls J.E., Murray P.J. A double agent in cancer: stopping macrophages wounds tumors. Nat. Med. 2010, 16(8):863-864.
97. Dickensheets H. Cytokine Mediated Stat Signaling is Feedback Inhibited By Socs Proteins, in Macrophages: Biology and Role in the Pathology of Diseases 2014, Springer, New York. S.M.A. Biswas (Ed.).
98. Naka T., et al. SOCS-1/SSI-1-deficient NKT cells participate in severe hepatitis through dysregulated cross-talk inhibition of IFN-gamma and IL-4 signaling in vivo. Immunity 2001, 14(5):535-545.
99. Whyte C.S., et al. Suppressor of cytokine signaling (SOCS)1 is a key determinant of differential macrophage activation and function. J. Leukoc. Biol. 2011, 90(5):845-854.
100. Liu Y., et al. Unique expression of suppressor of cytokine signaling 3 is essential for classical macrophage activation in rodents in vitro and in vivo. J. Immunol. 2008, 180(9):6270-6278.
101. Qin H., et al. SOCS3 deficiency promotes M1 macrophage polarization and inflammation. J. Immunol. 2012, 189(7):3439-3448.
102. Qin H., et al. Signal transducer and activator of transcription-3/suppressor of cytokine signaling-3 (STAT3/SOCS3) axis in myeloid cells regulates neuroinflammation. Proc. Natl. Acad. Sci. U.S.A. 2012, 109(13):5004-5009.
103. Fleetwood A.J., et al. GM-CSF- and M-CSF-dependent macrophage phenotypes display differential dependence on type I interferon signaling. J. Leukoc. Biol. 2009, 86(2):411-421.
104. Krausgruber T., et al. IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat. Immunol. 2011, 12(3):231-238.
105. Satoh T., et al. The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection. Nat. Immunol. 2010, 11(10):936-944.
106. Bonizzi G., Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 2004, 25(6):280-288.
107. Lawrence T., Fong C. The resolution of inflammation: anti-inflammatory roles for NF-kappaB. Int. J. Biochem. Cell Biol. 2010, 42(4):519-523.
108. Saccani A., et al. p50 Nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res. 2006, 66(23):11432-11440.
109. Kastenbauer S., Ziegler-Heitbrock H.W. NF-kappaB1 (p50) is upregulated in lipopolysaccharide tolerance and can block tumor necrosis factor gene expression. Infect. Immun. 1999, 67(4):1553-1559.
110. Porta C., et al. Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor kappaB. Proc. Natl. Acad. Sci. U.S.A. 2009, 106(35):14978-14983.
111. Riboldi E., et al. Hypoxia-mediated regulation of macrophage functions in pathophysiology. Int. Immunol. 2013, 25(2):67-75.
112. Takeda N., et al. Differential activation and antagonistic function of HIF-{alpha} isoforms in macrophages are essential for NO homeostasis. Genes Dev. 2010, 24(5):491-501.
113. Peyssonnaux C., et al. HIF-1alpha expression regulates the bactericidal capacity of phagocytes. J. Clin. Invest. 2005, 115(7):1806-1815.
114. Peyssonnaux C., et al. Cutting edge: essential role of hypoxia inducible factor-1alpha in development of lipopolysaccharide-induced sepsis. J. Immunol. 2007, 178(12):7516-7519.
115. Cramer T., et al. HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell 2003, 112(5):645-657.
116. Rius J., et al. NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature 2008, 453(7196):807-811.
117. Tawakol A., et al. HIF-1alpha and PFKFB3 mediate a tight relationship between proinflammatory activation and anerobic metabolism in atherosclerotic macrophages. Arterioscler. Thromb. Vasc. Biol. 2015, 35(6):1463-1471.
118. Leek R.D., et al. Relation of hypoxia-inducible factor-2 alpha (HIF-2 alpha) expression in tumor-infiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in Human breast cancer. Cancer Res. 2002, 62(5):1326-1329.
119. Mantovani A., et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002, 23(11):549-555.
120. Colegio O.R., et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature 2014, 513(7519):559-563.
121. Tripathi C., et al. Macrophages are recruited to hypoxic tumor areas and acquire a pro-angiogenic M2-polarized phenotype via hypoxic cancer cell derived cytokines Oncostatin M and Eotaxin. Oncotarget 2014, 5(14):5350-5368.
122. El Kasmi K.C., et al. Adventitial fibroblasts induce a distinct proinflammatory/profibrotic macrophage phenotype in pulmonary hypertension. J. Immunol. 2014, 193(2):597-609.
123. Imtiyaz H.Z., et al. Hypoxia-inducible factor 2alpha regulates macrophage function in mouse models of acute and tumor inflammation. J. Clin. Invest. 2010, 120(8):2699-2714.
124. Odegaard J.I., et al. Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance. Cell Metab. 2008, 7(6):496-507.
125. Kang K., et al. Adipocyte-derived Th2 cytokines and myeloid PPARdelta regulate macrophage polarization and insulin sensitivity. Cell Metab. 2008, 7(6):485-495.
126. Huang S.C., et al. Cell-intrinsic lysosomal lipolysis is essential for alternative activation of macrophages. Nat. Immunol. 2014, 15(9):846-855.
127. Zhu L., et al. Cellular metabolism and macrophage functional polarization. Int Rev Immunol. 2015, 34(1):82-100.
128. Tan Z., et al. Pyruvate dehydrogenase kinase 1 participates in macrophage polarization via regulating glucose metabolism. J. Immunol. 2015, 194(12):6082-6089.
129. Galic S., et al. Hematopoietic AMPK beta1 reduces mouse adipose tissue macrophage inflammation and insulin resistance in obesity. J. Clin. Invest. 2011, 121(12):4903-4915.
130. Chan K.L., et al. Palmitoleate reverses high fat-induced proinflammatory macrophage polarization via AMP-activated protein kinase (AMPK). J. Biol. Chem. 2015, 290(27):16979-16988.
131. Sag D., et al. Adenosine 5'-monophosphate-activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype. J. Immunol. 2008, 181(12):8633-8641.
132. Zhu Y.P., et al. Adenosine 5'-monophosphate-activated protein kinase regulates IL-10-mediated anti-inflammatory signaling pathways in macrophages. J. Immunol. 2015, 194(2):584-594.
133. Mounier R., et al. AMPKalpha1 regulates macrophage skewing at the time of resolution of inflammation during skeletal muscle regeneration. Cell Metab. 2013, 18(2):251-264.
134. Cao Z., et al. Role of Kruppel-like factors in leukocyte development, function, and disease. Blood 2010, 116(22):4404-4414.
135. Liao X., et al. Kruppel-like factor 4 regulates macrophage polarization. J. Clin. Invest. 2011, 121(7):2736-2749.
136. Mahabeleshwar G.H., et al. The myeloid transcription factor KLF2 regulates the host response to polymicrobial infection and endotoxic shock. Immunity 2011, 34(5):715-728.
137. Date D., et al. Kruppel-like transcription factor 6 regulates inflammatory macrophage polarization. J. Biol. Chem. 2014, 289(15):10318-10329.
138. Pello O.M., et al. Role of c-MYC in alternative activation of human macrophages and tumor-associated macrophage biology. Blood 2012, 119(2):411-421.
139. Arranz A., et al. Akt1 and Akt2 protein kinases differentially contribute to macrophage polarization. Proc. Natl. Acad. Sci. U.S.A. 2012, 109(24):9517-9522.
140. Yue S., et al. Myeloid PTEN deficiency protects livers from ischemia reperfusion injury by facilitating M2 macrophage differentiation. J. Immunol. 2014, 192(11):5343-5353.
141. Byles V., et al. The TSC-mTOR pathway regulates macrophage polarization. Nat. Commun. 2013, 4:p2834.
142. Ruffell D., et al. A CREB-C/EBPbeta cascade induces M2 macrophage-specific gene expression and promotes muscle injury repair. Proc. Natl. Acad. Sci. U.S.A. 2009, 106(41):17475-17480.
143. Van den Bossche J., et al. Macrophage polarization: the epigenetic point of view. Curr. Opin. Lipidol. 2014, 25(5):367-373.
144. Ivashkiv L.B. Epigenetic regulation of macrophage polarization and function. Trends Immunol. 2013, 34(5):216-223.
145. Chen X., et al. Requirement for the histone deacetylase Hdac3 for the inflammatory gene expression program in macrophages. Proc. Natl. Acad. Sci. U.S.A. 2012, 109(42):E2865-E2874.
146. Mullican S.E., et al. Histone deacetylase 3 is an epigenomic brake in macrophage alternative activation. Genes Dev. 2011, 25(23):2480-2488.
147. Shakespear M.R., et al. Histone deacetylases as regulators of inflammation and immunity. Trends Immunol. 2011, 32(7):335-343.
148. Nicodeme E., et al. Suppression of inflammation by a synthetic histone mimic. Nature 2010, 468(7327):1119-1123.
149. Belkina A.C., Nikolajczyk B.S., Denis G.V. BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses. J. Immunol. 2013, 190(7):3670-3678.
150. Kittan N.A., et al. Cytokine induced phenotypic and epigenetic signatures are key to establishing specific macrophage phenotypes. PLoS ONE 2013, 8(10):pe78045.
151. Ishii M., et al. Epigenetic regulation of the alternatively activated macrophage phenotype. Blood 2009, 114(15):3244-3254.
152. De Santa F., et al. Jmjd3 contributes to the control of gene expression in LPS-activated macrophages. EMBO J. 2009, 28(21):3341-3352.
153. Yan Q., et al. Jmjd3-mediated epigenetic regulation of inflammatory cytokine gene expression in serum amyloid A-stimulated macrophages. Cell Signal. 2014, 26(9):1783-1791.
154. Kruidenier L., et al. A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature 2012, 488(7411):404-408.
155. Yasui T., et al. Epigenetic regulation of osteoclast differentiation: possible involvement of Jmjd3 in the histone demethylation of Nfatc1. J. Bone Miner. Res. 2011, 26(11):2665-2671.
156. Liu G., Abraham E. MicroRNAs in immune response and macrophage polarization. Arterioscler. Thromb. Vasc. Biol. 2013, 33(2):170-177.
157. Graff J.W., et al. Identifying functional microRNAs in macrophages with polarized phenotypes. J. Biol. Chem. 2012, 287(26):21816-21825.
158. Cobos Jimenez V., et al. Next-generation sequencing of microRNAs uncovers expression signatures in polarized macrophages. Physiol. Genomics 2014, 46(3):91-103.
159. O'Neill L.A., Sheedy F.J., McCoy C.E. MicroRNAs: the fine-tuners of Toll-like receptor signalling. Nat. Rev. Immunol. 2011, 11(3):163-175.
160. Taganov K.D., et al. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc. Natl. Acad. Sci. U.S.A. 2006, 103(33):12481-12486.
161. Bazzoni F., et al. Induction and regulatory function of miR-9 in human monocytes and neutrophils exposed to proinflammatory signals. Proc. Natl. Acad. Sci. U.S.A. 2009, 106(13):5282-5287.
162. Sheedy F.J., et al. Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nat. Immunol. 2010, 11(2):141-147.
163. Androulidaki A., et al. The kinase Akt1 controls macrophage response to lipopolysaccharide by regulating microRNAs. Immunity 2009, 31(2):220-231.
164. O'Connell R.M., et al. Inositol phosphatase SHIP1 is a primary target of miR-155. Proc. Natl. Acad. Sci. U.S.A. 2009, 106(17):7113-7118.
165. Bala S., et al. Up-regulation of microRNA-155 in macrophages contributes to increased tumor necrosis factor {alpha} (TNF{alpha}) production via increased mRNA half-life in alcoholic liver disease. J. Biol. Chem. 2011, 286(2):1436-1444.
166. McCoy C.E., et al. IL-10 inhibits miR-155 induction by toll-like receptors. J. Biol. Chem. 2010, 285(27):20492-20498.
167. Du F., et al. MicroRNA-155 deficiency results in decreased macrophage inflammation and attenuated atherogenesis in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2014, 34(4):759-767.
168. Nazari-Jahantigh M., et al. MicroRNA-155 promotes atherosclerosis by repressing Bcl6 in macrophages. J. Clin. Invest. 2012, 122(11):4190-4202.
169. Martinez-Nunez R.T., Louafi F., Sanchez-Elsner T. The interleukin 13 (IL-13) pathway in human macrophages is modulated by microRNA-155 via direct targeting of interleukin 13 receptor alpha1 (IL13Ralpha1). J. Biol. Chem. 2011, 286(3):1786-1794.
170. Louafi F., Martinez-Nunez R.T., Sanchez-Elsner T. MicroRNA-155 targets SMAD2 and modulates the response of macrophages to transforming growth factor-{beta}. J. Biol. Chem. 2010, 285(53):41328-41336.
171. Cai X., et al. Re-polarization of tumor-associated macrophages to pro-inflammatory M1 macrophages by microRNA-155. J. Mol. Cell Biol. 2012, 4(5):341-343.
172. Veremeyko T., et al. IL-4/IL-13-dependent and independent expression of miR-124 and its contribution to M2 phenotype of monocytic cells in normal conditions and during allergic inflammation. PLoS ONE 2013, 8(12):pe81774.
173. Ponomarev E.D., et al. MicroRNA-124 promotes microglia quiescence and suppresses EAE by deactivating macrophages via the C/EBP-alpha-PU.1 pathway. Nat. Med. 2011, 17(1):64-70.
174. Lee B., et al. C/EBPalpha regulates macrophage activation and systemic metabolism. Am. J. Physiol. Endocrinol. Metab. 2014, 306(10):E1144-E1154.
175. Yamamoto M., et al. CCAAT/enhancer binding protein alpha (C/EBPalpha)(+) M2 macrophages contribute to fibrosis in IgG4-related disease?. Mod. Rheumatol. 2015, 25(3):484-486.
176. Zhuang G., et al. A novel regulator of macrophage activation: miR-223 in obesity-associated adipose tissue inflammation. Circulation 2012, 125(23):2892-2903.
177. Chaudhuri A.A., et al. MicroRNA-125b potentiates macrophage activation. J. Immunol. 2011, 187(10):5062-5068.
178. Banerjee S., et al. miR-125a-5p regulates differential activation of macrophages and inflammation. J. Biol. Chem. 2013, 288(49):35428-35436.
179. Banerjee S., et al. MicroRNA let-7c regulates macrophage polarization. J. Immunol. 2013, 190(12):6542-6549.
180. Garofalo R.S., et al. Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB beta. J. Clin. Invest. 2003, 112(2):197-208.
181. Kadl A., et al. Identification of a novel macrophage phenotype that develops in response to atherogenic phospholipids via Nrf2. Circ. Res. 2010, 107(6):737-746.
182. Gobert A.P., et al. Heme oxygenase-1 dysregulates macrophage polarization and the immune response to Helicobacter pylori. J. Immunol. 2014, 193(6):3013-3022.
183. Cavaillon J.M., Adib-Conquy M. Bench-to-bedside review: endotoxin tolerance as a model of leukocyte reprogramming in sepsis. Crit. Care 2006, 10(5):p233.
184. Stearns-Kurosawa D.J., et al. The pathogenesis of sepsis. Annu. Rev. Pathol. 2011, 6:19-48.
185. Hotchkiss R.S., et al. The sepsis seesaw: tilting toward immunosuppression. Nat. Med. 2009, 15(5):496-497.
186. Boomer J.S., et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 2011, 306(23):2594-2605.
187. Biswas S.K., Lopez-Collazo E. Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends Immunol. 2009, 30(10):475-487.
188. Shalova I.N., et al. Human monocytes undergo functional re-programming during sepsis mediated by hypoxia-inducible factor-1alpha. Immunity 2015, 42(3):484-498.
189. Foster S.L., Hargreaves D.C., Medzhitov R. Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature 2007, 447(7147):972-978.
190. Lou Y., et al. TIPE2 negatively regulates inflammation by switching arginine metabolism from nitric oxide synthase to arginase. PLoS ONE 2014, 9(5):e96508.
191. Chen X., et al. The NF-kappaB factor RelB and histone H3 lysine methyltransferase G9a directly interact to generate epigenetic silencing in endotoxin tolerance. J. Biol. Chem. 2009, 284(41):27857-27865.
192. Yan Q., et al. Nuclear factor-kappaB binding motifs specify Toll-like receptor-induced gene repression through an inducible repressosome. Proc. Natl. Acad. Sci. U.S.A. 2012, 109(35):14140-14145.
193. Liu T.F., et al. NAD+-dependent SIRT1 deacetylase participates in epigenetic reprogramming during endotoxin tolerance. J. Biol. Chem. 2011, 286(11):9856-9864.
194. Chen J., Ivashkiv L.B. IFN-gamma abrogates endotoxin tolerance by facilitating Toll-like receptor-induced chromatin remodeling. Proc. Natl. Acad. Sci. U.S.A. 2010, 107(45):19438-19443.
195. Ho P.C., et al. NF-kappaB-mediated degradation of the coactivator RIP140 regulates inflammatory responses and contributes to endotoxin tolerance. Nat. Immunol. 2012, 13(4):379-386.
196. Saeed S., et al. Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity. Science 2014, 345(6204):p1251086.
197. Cheng S.C., et al. mTOR- and HIF-1alpha-mediated aerobic glycolysis as metabolic basis for trained immunity. Science 2014, 345(6204):p1250684.
198. Suzuki T., et al. Pulmonary macrophage transplantation therapy. Nature 2014, 514(7523):450-454.
199. Happle C., et al. Pulmonary transplantation of macrophage progenitors as effective and long-lasting therapy for hereditary pulmonary alveolar proteinosis. Sci. Transl. Med. 2014, 6(250). 250ra113.
200. Allavena P., et al. Intraperitoneal recombinant gamma-interferon in patients with recurrent ascitic ovarian carcinoma: modulation of cytotoxicity and cytokine production in tumor-associated effectors and of major histocompatibility antigen expression on tumor cells. Cancer Res. 1990, 50(22):7318-7323.
201. Colombo N., et al. Anti-tumor and immunomodulatory activity of intraperitoneal IFN-gamma in ovarian carcinoma patients with minimal residual tumor after chemotherapy. Int. J. Cancer 1992, 51(1):42-46.
202. Beatty G.L., et al. A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin. Cancer Res. 2013, 19(22):6286-6295.
203. Kratochvill F., et al. TNF counterbalances the emergence of M2 tumor macrophages. Cell Rep. 2015, 12(11):1902-1914.
204. Orr J.S., et al. Toll-like receptor 4 deficiency promotes the alternative activation of adipose tissue macrophages. Diabetes 2012, 61(11):2718-2727.
205. Potian J.A., et al. Preexisting helminth infection induces inhibition of innate pulmonary anti-tuberculosis defense by engaging the IL-4 receptor pathway. J. Exp. Med. 2011, 208(9):1863-1874.
206. Tundup S., et al. CD14 influences host immune responses and alternative activation of macrophages during Schistosoma mansoni infection. Infect. Immun. 2014, 82(8):3240-3251.
207. Simonatto M., Natoli G. Functional genomics of the inflammatory response: where are we now?. Brief. Funct. Genomics 2013, 12(6):483-488.